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Acute vascular effects of vascular endothelial growth
factor inhibition in the forearm arterial circulation
Alan C. Camerona, Paul Welsha, Karla B. Nevesa, David E. Newbyb, Rhian M. Touyza,
and Ninian N. Langa
Objective: Although vascular endothelial growth factor
inhibition (VEGFi) represents a major therapeutic advance
in oncology, it is associated with hypertension and adverse
vascular thrombotic events. Our objective was to
determine whether VEGFi caused direct vascular
dysfunction through increased endothelin-1 (ET-1) activity
or impaired endothelial vasomotor or fibrinolytic function.
Methods: Using forearm venous occlusion
plethysmography, we measured forearm blood flow
dur ing intra-arter ia l infus ions of bevac izumab
(36–144mg/dl forearm volume per minute) administered
for 15–60min in healthy volunteers (n¼6–8). On two
separate occasions in 10 healthy volunteers, we further
measured forearm blood flow and tissue plasminogen
activator (t-PA) release during intra-arterial bradykinin
infusion (100 and 1000 pmol/min) in the presence and
absence of bevacizumab (144mg/dl forearm volume per
minute), and the presence and absence of endothelin A
receptor antagonism with BQ-123 (10 nmol/min). Plasma
t-PA and plasminogen activator inhibitor-1 (PAI-1)
concentrations were measured at baseline and with
each dose of bradykinin.
Results: Baseline blood flow and plasma ET-1, t-PA and
PAI-1 concentrations were unaffected by bevacizumab.
Bradykinin caused dose-dependent vasodilatation
(P<0.0001) and t-PA release (P<0.01) but had no effect
on plasma PAI-1 concentrations. Neither bevacizumab nor
BQ-123 affected bradykinin-induced vasodilatation and
t-PA release.
Conclusion: Acute exposure to bevacizumab does not
directly cause endothelial vasomotor or fibrinolytic
dysfunction in healthy young volunteers.
Keywords: bevacizumab, endogenous fibrinolysis,
endothelin-1, endothelium-dependent vasodilatation,
forearm arterial vasomotor function, hypertension,
neoangiogenesis, vascular endothelial growth factor
inhibitor
Abbreviations: ACh, acetylcholine; BP, blood pressure;
BVZ, bevacizumab; EDHF, endothelium-derived
hyperpolarizing factor; ET-1, endothelin-1; ETAR,
endothelin-A receptor; FBF, forearm blood flow; Hct,
haematocrit; NO, nitric oxide; PAI-1, plasminogen activator
inhibitor type 1; t-PA, tissue plasminogen activator; VEGF,
vascular endothelial growth factor; VEGFi, vascular
endothelial growth factor inhibitor
INTRODUCTION
V
ascular endothelial growth factor (VEGF) plays a key
role in tumour growth and metastasis by stimulating
neoangiogenesis, the formation of new blood vessels
from pre-existing vasculature [1]. VEGF inhibition (VEGFi) is
a major therapeutic advance for patients with previously
untreatable cancers. Bevacizumab, the first VEGFi to be
approved for clinical use, is a monoclonal antibody against
VEGF. Small molecule VEGF tyrosine kinase inhibitors rep-
resent the other main class of VEGFi (e.g. sunitinib, pazo-
panib). However, these drugs are frequently associated with
cardiovascular toxicities, of which systemic hypertension is
the most common [1–4]. Almost every trial of VEGFi reports a
treatment-associated increase in blood pressure (BP) and up
to 80% of patients develop hypertension [1–3,5,6]. This can
be difficult to treat and may limit the use of this therapy.
VEGFi also increases the risk of arterial [7] and venous [8]
thrombotic events over and above the pro-coagulant effects
of malignancy [1,7].
Mechanisms underlying the unwanted vascular effects of
VEGFi remain incompletely defined. Acute impairment of
endothelium-dependent vasodilatation to acetylcholine has
previously been demonstrated following brief exposure to
a locally active dose of intra-arterial bevacizumab in the
forearm arterial circulation of healthy volunteers [9]. Fur-
thermore, plasma concentrations of endothelin 1 (ET-1), a
potent vasoconstrictor, increase after treatment with VEGFi
[10–14] and ET-1 receptor (ETR) antagonism prevents
VEGFi-induced BP rise in animals [12,15,16]. Current
anti-hypertensive therapies used for the treatment of
patients with VEGFi-associated hypertension are generic
and not pathophysiologically targeted.
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The risk of thrombosis associated with VEGFi may relate
to altered fibrinolysis. Tissue plasminogen activator (t-PA)
is a serine protease that regulates fibrinolysis and is a
marker of endothelial function. Its actions are counterbal-
anced by plasminogen activator inhibitor type 1 (PAI-1), a
serpin that prevents excessive systemic fibrinolytic activity.
The overall balance of fibrinolysis is thus important for the
prevention of intravascular thrombosis and predicts the
future risk of cardiovascular events [17].
We investigated the acute vasomotor and endogenous
fibrinolytic effects of locally administered bevacizumab in
the forearm arterial circulation of healthy volunteers. Spe-
cifically, we assessed dose-dependent effects of bevacizu-
mab on resting vascular tone and bradykinin-induced
endothelium-dependent vasodilator and endogenous fibri-
nolytic responses. With the aim of assessing ET-1 as a
potential mediator of VEGFi-induced vascular actions,
these assessments were made in the presence and absence
of concurrent endothelin receptor antagonism.
METHODS
The clinical study protocol (NCT03557190) was approved
by the West of Scotland Research Ethics Committee 4 and
carried out in accordance with the principles of the Decla-
ration of Helsinki. Written informed consent was obtained
from all participants prior to the study.
Study participants
Healthy male volunteers were studied to avoid the potential
for menstrual cycle-related changes in vascular function
and to avoid potential latent teratogenicity in case of
systemic spill-over of bevacizumab. Exclusion criteria
included cardiovascular disease, hypertension, hyperlipi-
daemia, cerebrovascular disease, ischaemic heart disease,
heart failure, atrial fibrillation/flutter, prior thrombotic/
thromboembolic event, renal failure or hepatic failure,
chronic medication, cigarette smoking, recreational drug
use, history of anaemia, cancer, diabetes or macular degen-
eration, ongoing inflammatory, infective or autoimmune
disease, live vaccination in the past 3 months or expected in
the next 6 months, and BMI greater than 35 kg/m2.
Forearm venous occlusion plethysmography
All studies were performed by a single investigator with the
patient lying supine in a quiet, temperature-controlled (22–
24 8C) room. Participants fasted for 4 h, abstained from
alcohol for 24 h and did not consume any medications
for 3 days before each study. Venous cannulae (17 gauge)
were inserted into large subcutaneous veins of both ante-
cubital fossae to facilitate venous sampling.
Brachial artery cannulation was performed using a 27-
standard-wire-gauge steel needle. The total intra-arterial infu-
sion rate was maintained at 1ml/min throughout all studies.
Forearm blood flow was measured in the infused and non-
infused arms by venous occlusion plethysmography using
mercury-in-silastic strain gauges (Hokanson EC4; Hokanson,
Inc., Bellevue, Washington, USA), as described previously
[18,19]. Supine heart rate and blood pressure were monitored
at intervals throughout each study using a semiautomated,
noninvasiveoscillometric sphygmomanometer. The first three
participants in each phase of the study returned for clinical
review and repeat blood tests (full blood count, renal func-
tion/electrolytes, liver function tests, coagulation screen and
glucose) to ensure safety and all other participants were
contacted by telephone the day after each visit.
Drugs
Pharmaceutical grade bradykinin (Bachem AG, Switzerland),
BQ-123 (Bachem AG, Bubendorf, Switzerland) and bevaci-
zumab (Roche Pharma AG, Grenzach-Wyhlen, Germany)
were dissolved in physiological saline.
Intra-arterial drug administration
Protocol 1: effects of vascular endothelial growth
factor inhibition on resting forearm blood flow in
healthy males
After a 20-min equilibration phase of intra-arterial 0.9%
sodium chloride infusion, intra-arterial bevacizumab was
infused for 15min at a constant dose of 36, 72 or 144mg/dl
forearm volume per min (n¼ 6, 6 and 8, respectively;
Fig. 1a). Bevacizumab administered intra-arterially for
15min at 144mg/dl forearm volume per minute produces
local forearm arterial concentrations similar to the plasma
concentrations of bevacizumab found in patients after a
clinically relevant intravenous dose of 5mg/kg bevacizu-
mab [9]. A further eight participants received a 60-min
infusion of bevacizumab delivered at 36mg/dl forearm
volume per minute to explore the effects of longer expo-
sure (Fig. 1b). Forearm blood flow was measured at 4-min
intervals during the infusion of bevacizumab and at 10-min
intervals for a total of 120min thereafter.
Protocol 2: effects of vascular endothelial growth
factor inhibition on stimulated blood flow,
endogenous fibrinolysis and the effect of
endothelin-receptor antagonism in healthy men
A separate group of 10 healthy male volunteers attended for
two visits, each separated by at least 14 days. Following a
20-min equilibration phase, bradykinin (100 and
1000 pmol/min), an endothelium-dependent vasodilator
that stimulates endothelial t-PA release, was infused for
6min at each dose, first in the absence and then in the
presence of bevacizumab 144mg/dl for 15min. There was a
20-min washout between infusions. Double-blind random-
ization was performed at visit 1 to co-infusion of BQ-123
10 nmol/min (ETAR antagonist) or placebo (0.9% physio-
logical saline), and the alternative agent was infused at visit
2. BQ-123 and placebo were infused for 90 min before
bradykinin assessments to allow steady-state ETAR antago-
nism from BQ-123 [20] (Fig. 2).
Blood sampling
Venous blood was collected at baseline for full blood count,
renal function and electrolytes, liver function, lipid profile
and glucose concentration. Blood samples were drawn
from both arms at intervals during and after bevacizumab
infusion, and with each dose of bradykinin, into serum
tubes (BD Vacutainer, UK) for ET-1 assays, acidified buff-
ered citrate (Stabilyte) tubes for t-PA assays and citrate tubes
(BD Vacutainer) for PAI-1 assays. Samples were kept on ice
before centrifugation at 2000 rpm for 10min. Platelet-free
plasma was decanted and stored at 80 8C before assay.
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FIGURE 1 Overview of intra-arterial infusions and blood sampling. Protocol 1: effects of VEGFi on resting forearm blood flow; (a) bevacizumab 36, 72 or 144mg/dl forearm
volume per minute for 15min, (b) Bevacizumab 36mg/dl forearm volume per minute for 60min. FBF, forearm blood flow; BVZ, bevacizumab. VEGFi, vascular endothelial
growth factor inhibition.
Placebo
BQ-123
Saline Bevacizumab
BK
Visit 1
Visit 2
FBF Measurement
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1000
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1000
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FIGURE 2 Overview of intra-arterial infusions and blood sampling. Protocol 2: the effect of VEGFi on stimulated forearm arterial vasodilatation and release of endogenous
fibrinolytic factors. 100, 100 pmol/minute; 1000, 1000pmol/minute; BK, bradykinin; BQ-123, BQ-123, 10nmol/minute; FBF, forearm blood flow; bevacizumab, bevacizu-
mab 144mg/dl forearm volume per minute for 15min; placebo, 0.9% saline. VEGFi, vascular endothelial growth factor inhibition.
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Measurement of plasma endothelin-1, tissue
plasminogen activator and plasminogen activator
inhibitor-1
ELISAs were performed to determine concentrations of
endothelin-1 (human Endothelin-1 QuantiGlo ELISA Kit,
QET00B; R&D Systems, Abingdon, UK), tissue plasminogen
activator (Asserachrom t-PA, 00948; Stago, Reading, UK),
plasminogen activator inhibitor-1 (PAI-1) antigen (Asser-
achrom PAI-1, 00949; Stago), and PAI-1 activity (Active
Human PAI-1 functional assay kit, PI90; Oxford Biomedical
Research, 2B Scientific, UK).
Data analysis and statistics
Forearm plethysmographic data were analyzed as described
previously [21]. The primary outcome was absolute forearm
blood flow. Assessment of potential vasoconstrictor
responsewas also analyzed as percentage change in forearm
blood flow from baseline [22]. The estimated net release of
plasma ET-1, t-PA and PAI-1 was defined as the product of
the infused forearmplasma flow, based on haematocrit (Hct)
and infused forearm blood flow, and the concentration
difference between the infused and noninfused arms [21].
Variables are reported as mean  SEM and were analysed
using repeated measures ANOVA with post hoc correction
for multiple comparison. Statistical analysis was performed
using GraphPad Prism (GraphPad Software, San Diego,
California, USA; Version 7) with statistical significance at 5%.
RESULTS
Participant characteristics
Thirty-eight healthy men aged between 18 and 52 years
participated (mean age 25 years). Baseline demographics
are presented in Table 1.
Protocol 1: the effect of vascular endothelial
growth factor inhibition on basal forearm
arterial tone and the release of endothelin-1
Baseline forearm arterial blood flow
Resting absolute forearm blood flow remained unchanged
in the infused and noninfused arms when bevacizumabwas
administered at concentrations of 36, 72 and 144mg/dl
forearm volume per minute for 15min, and 36mg/dl fore-
arm volume per minute for 60min (P¼NS for all; Fig. 3).
When analysed as percentage change in forearm blood
flow from baseline and as a ratio of infused : noninfused
forearm blood flow, blood flow was again unchanged by
bevacizumab at all doses and infusion durations (P¼NS for
all; data not shown).
The effect of vascular endothelial growth factor
inhibition on endothelin-1 release
Baseline net ET-1 release was 0.06 0.10 pg/100ml/min
and was unchanged during and after bevacizumab infusion
at 144mg/dl forearm volume per minute for 15min
(P¼ 0.24) or 36mg/dl forearm volume per minute for
60min (P¼ 0.42). There was no change in net ET-1 con-
centration at any time (P¼NS for all, Fig. 4).
Protocol 2: the effect of vascular endothelial
growth factor inhibition on bradykinin-induced
vasodilatation and release of fibrinolytic
factors in the presence and absence of
endothelin-receptor antagonism
The effect of vascular endothelial growth factor
inhibition on bradykinin-induced vasodilatation
Intra-arterial bradykinin infusion evoked a dose-dependent
vasodilatation (P< 0.0001; Fig. 5) that was unaffected by
the presence of bevacizumab 144mg/dl forearm volume
per minute for 15min (P¼ 0.45; Fig. 5).
The effect of vascular endothelial growth factor
inhibition on bradykinin-induced tissue
plasminogen activator and plasminogen activator
inhibitor-1 release
Baseline net t-PA antigen release was 2.12 3.65 ng/
100ml/min. This was unaffected by the presence of bev-
acizumab (P¼ 0.63). Bradykinin evoked dose-dependent
release of net t-PA antigen (net t-PA antigen:
45.56 11.06 ng/100ml/min in the presence of bradykinin
100 pmol/min; 269.46 58.47 ng/100ml/min in the pres-
ence of bradykinin 1000 pmol/min; P< 0.01 for dose–
response). This response was unaffected by the presence
TABLE 1. Demographics of study participants
Protocol 1: resting Protocol 2: BK-stimulated
Infusion (s)
BVZ 36mg/dl,
15 min
BVZ 72mg/dl,
15 min
BVZ 144mg/dl,
15 min
BVZ 36mg/dl,
60 min
BVZ 144mg/dl 15min
with BKBQ-123
Participants (n) 6 6 8 8 10
Age (years) 22.61.9 29.85.9 25.92.3 24.71.5 23.51.5
Height (m) 177.74.2 183.42.1 176.42.6 180.61.9 179.31.4
Weight (kg) 74.64.2 79.65.3 69.22.9 69.72.4 75.62.3
BMI (kg/m2) 23.61.1 23.41.2 22.31.1 21.40.8 23.50.7
SBP (mmHg) 1225 1273 1244 1183 1223.4
DBP (mmHg) 733 774 763 673 703
Heart rate (bpm) 673 602 654 593 613
Haemoglobin (g/l) 1506 1597 1552 1483.6 1503
Glucose (mmol/l) 4.70.1 4.60.3 4.60.1 4.70.2 4.60.2
Cholesterol (mmol/l) 3.40.7 5.50.5 4.60.5 3.90.1 4.60.4
Triglycerides (mmol/l) 1.00.1 1.40.2 1.00.1 0.70.1 0.90.1
BVZ, bevacizumab; BK, Bradykinin; bpm, beats per minute.
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of bevacizumab (P¼ 0.49 for dose–response bradykinin-
induced net t-PA Ag release in the presence versus the
absence of bevacizumab). Net release of PAI-1 antigen and
activity at rest were 0.22 2.07 ng/100ml/min and
2.41 3.13 IU/100ml/min, respectively. Bradykinin was
not associated with a change in net PAI-1 antigen (P¼ 0.77)
or activity (P¼ 0.14) and was unaffected by the presence of
bevacizumab (P¼NS for all).
The effect of endothelin-receptor antagonism on
bradykinin-induced vasodilatation and fibrinolytic
factor release in the presence of vascular
endothelial growth factor inhibition
Intra-arterial infusion of BQ-123 at 10 nmol/min increased
forearm blood flow in the infused arm from 1.79 0.19 to
2.32 0.31ml/100ml/min at 80min (P< 0.001). BQ-123
did not alter the vasodilator dose–response to bradykinin
in the presence or absence of bevacizumab co-infusion
(P¼ 0.73 and P¼ 0.52, respectively; Fig. 6). Dose-depen-
dent bradykinin-induced t-PA antigen release was unaf-
fected by BQ-123 in the presence of bevacizumab
(P¼ 0.66). Net release of PAI-1 antigen and activity
remained unchanged in response to bradykinin in the
presence and absence of BQ-123 and irrespective of the
presence or absence of bevacizumab (P¼NS for all).
DISCUSSION
We have comprehensively characterized the acute and
direct effects of bevacizumab on endothelial vasomotor
tone and endogenous fibrinolytic function using invasive
sensitive gold standard measures of endothelial and vascu-
lar function. We have demonstrated that bevacizumab does
not alter resting endothelial function or vascular tone and
has no effect on plasma ET-1 concentrations. Moreover,
VEGFi does not influence endogenous vasomotor or fibri-
nolytic responses to bradykinin. These data indicate that the
VEGFi bevacizumab has no acute effects on vascular func-
tion, endothelial release of fibrinolytic factors and ET-1
production in healthy men.
Prior work examined the effect of a single acute dose of
bevacizumab in the forearm arterial circulation and
revealed no change in resting forearm arterial tone during
intermittent assessment for 45min [9]. In our study, bev-
acizumab also had no effect on resting arterial tone or net
release of ET-1 for up to 2 h following its administration. We
examined the effects of ascending doses of bevacizumab
and the maximum dose given (144mg/dl forearm volume
per minute) produced a local forearm arterial concentration
that reflects systemic concentrations achieved in patients
treated with 5mg/kg bevacizumab intravenously [9]. The
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FIGURE 3 Absolute forearm blood flow in the infused arm (solid line) and noninfused arm (dashed line) during and after administration of bevacizumab. (a) 36, (b) 72 and
(c) 144mg/dl forearm volume per minute for 15min, followed by 0.9% saline for 105min and, (d) 36mg/dl forearm volume per minute for 60min, followed by 0.9%
saline for 60min. BVZ, bevacizumab; vol, volume.
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vasoconstrictor effect of ET-1 is relatively slow in onset,
taking at least 60min for its full effects to manifest and
plateau [23]. Therefore, by continuing observations for 2 h,
we were able to make a more definitive conclusion that
bevacizumab does not affect resting forearm vascular tone.
Furthermore, by administering bevacizumab over a more
prolonged period (1 h), we were unable to show that the
increased time of vascular exposure to bevacizumab trans-
lates into a vasoconstrictor response in comparison to the
shorter 15min period of administration.
Forearm plethysmography is a robust method to mea-
sure vascular function in humans [18,24]. The current study
was motivated by previous reports that endothelium-
dependent vasodilatation in response to intra-arterial ace-
tylcholine (ACh) is reduced by bevacizumab in a similar
protocol to that used in our study [9]. In contrast to previous
data, we did not observe impaired endothelium-dependent
vasodilator response to bradykinin in the presence of
bevacizumab. Important factors in this apparent discrep-
ancy warrant discussion. First, a proportion of apparently
healthy people are said to be acetylcholine ‘non-respond-
ers’ and were excluded from the final analysis of the
previous study [9] and may have led to a type 2 error.
However, bradykinin is much less susceptible to such
inter-individual variation. Second, as the mechanisms of
acetylcholine and bradykinin-induced vasodilatation may
differ, VEGFi may differentially influence these mecha-
nisms. Third, it is conventional to report and compare
forearm arterial vasodilator effects as absolute blood flow
rather than as a percentage change from baseline, which is
associated with greater variability and can be affected
disproportionately by small changes in baseline flow [25].
We present our data in terms of absolute blood flow
responses. When analysed as percentage change from
baseline or the ratio of absolute blood flow in infused :
noninfused forearm, our results remain consistent. We,
therefore, propose that our findings are valid.
It is of note that acetylcholine-evoked vasodilatation is
mediated predominantly via nitric oxide (NO) [26]. In
contrast, bradykinin invokes a greater relative contribution
from endothelium-derived hyperpolarizing factor (EDHF)
[27]. In addition to methodological differences, it is possible
that the apparently different findings between our study
and those of Thijs et al reflect this. Indeed, decreased NO
bioavailability in the setting of VEGFi has been demon-
strated in both preclinical models and in patients, and
therefore, this may be more apparent when endothelial
responses are assessed with acetylcholine than with brady-
kinin. However, our findings are also consistent with the
observation that acetylcholine-mediated vasodilatation is
unaffected in patients treated with sunitinib (a tyrosine
kinase inhibitor of VEGF) for 1 week [28].
Unlike acetylcholine, bradykinin evokes the release of
the endogenous fibrinolytic factor, t-PA. The assessment of
this endothelial pathway is relevant not only as a sensitive
and prognostic marker of vascular health [17] but is also
relevant to assessing the putative endothelial mechanism
underlying VEGFi-associated thrombosis. We demonstrate
that although bradykinin is a potent agonist of t-PA release,
this is not acutely affected by bevacizumab. Whether or not
stimulated t-PA release is impaired in the setting of chronic
exposure to VEGFi remains to be assessed, and it is also
possible that older patients with co-morbidity and pre-
existing endothelial dysfunction are more susceptible to
effects of VEGFi. Given that both venous [8] and arterial [7]
thromboembolism are increased in patients treated with
bevacizumab, it is unlikely that this can be explained as a
direct effect of arterial hypertension alone. In the context of
the inflammatory and prothrombotic milieu of malignancy,
relatively minor perturbations in the endogenous fibrino-
lytic pathway could contribute to VEGFi-associated throm-
bosis. Neither bradykinin nor bevacizumab affected the
net release of PAI-1, the major endogenous inhibitor of
t-PA activity.
In the absence of an effect of bevacizumab on endothe-
lium-dependent vasodilatation, the conclusions that can be
drawn from the lack of effect from endothelin receptor
antagonism are constrained. It is clear, however, that BQ-
123 does not potentiate bradykinin-evoked vasodilatation
in the presence of bevacizumab in healthy people. How-
ever, BQ-123 has previously been demonstrated to increase
acetylcholine-stimulated forearm arterial blood flow in
patients with atherosclerosis but not in healthy people
[29]. Therefore, the interplay between baseline cardiovas-
cular risk and associated up-regulation of the ET-1 signal-
ling pathway may mean that the situation is different in
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FIGURE 4 Net forearm endothelin-1 release during and after administration of
bevacizumab. (a) 144mg/dl forearm volume per minute for 15min, followed by
0.9% saline for 105 min (n¼8) and (b) 36mg/dl forearm volume per minute for
60min, followed by 0.9% saline for 60 min (n¼8). ET-1, endothelin-1; BVZ,
bevacizumab; vol, volume.
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FIGURE 5 Absolute forearm blood flow in response to bradykinin 100 and 1000pmol/minute in the presence and absence of bevacizumab 144mg/dl forearm volume per
minute for 15min. Squares represent assessment in the presence of bevacizumab and circles represent assessment in the absence of bevacizumab (n¼10). Solid lines,
infused arm; dashed lines, noninfused arm.
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FIGURE 6 Absolute forearm blood flow in response to bradykinin 100 and 1000 pmol/min in the presence of intra-arterial bevacizumab 144mg/dl forearm volume per
minute for 15min, with BQ-123 10nmol per minute or placebo. Diamonds represent BQ-123 and triangles represent placebo. Solid lines, infused arm; dashed lines,
noninfused arm.
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patients treated with VEGFi. Furthermore, up-regulation of
ET-1 activity and bioavailability is a consistent feature of
preclinical models of VEGFi and in cancer patients treated
with these drugs [10–13]. BQ-123 is a selective ET-A recep-
tor antagonist and we did not examine the effect of com-
bined ET-A and ET-B receptor antagonism. Although the
vasomotor effect of isolated ET-B activation is vasodilata-
tion, the net effect of combined ET-A and ET-B activation
remains to be potent vasoconstriction evoked via the
strongly dominant effect of ET-A activation [30]. We believe
it to be unlikely that additional ET-B antagonism would
alter our findings.
Although we have not demonstrated an acute VEGFi-
induced alteration in vasomotor activity, it remains plausi-
ble that ET-1 is up-regulated in patients following longer
exposure to VEGFi, potentially in association with reduced
NO bioavailability [9,31,32]. The chronic effects of VEGFi
upon blood pressure may also reflect contributions from
multiple pathogenic mechanisms including renal dysfunc-
tion, vascular rarefaction, oxidative stress and salt sensitivity
[1,31,32].
The role of NO in vasomotor and fibrinolytic changes
induced by VEGFi could be further explored by conducting
assessments in the presence of the NO synthase inhibitor,
Nv-Methyl-L-arginine acetate (L-NMMA). EDHF may be up-
regulated in the setting of impaired NO bioavailability and
the assessment of VEGFi upon EDHF-mediated vasomotor
effects would be relevant. Further credence to this
approach is provided by the observation that EDHF is
exclusively responsible for bradykinin-induced t-PA release
in patients with essential hypertension [33]. These assess-
ments of the effects of VEGFi upon EDHF-mediated activity
could be performed in the human forearm using intra-
arterial sulfaphenazole, an inhibitor of cytochrome P450
2C9 that acts as an antagonist of EDHF.
Our studies have some limitations that should be con-
sidered. These assessments were conducted in healthy
individuals where VEGF levels are not elevated and endo-
thelial function is presumed to be normal. Thus, inhibiting
VEGF signalling may be ineffective in this group and may
not reflect the situation in patients with cancer or previous
cardiovascular disease (CVD). We have no evidence of
whether VEGF signalling was indeed inhibited by bevaci-
zumab in the forearm vessels studied. The maximum dose
of bevacizumab we administered achieves local forearm
arterial concentrations comparable with the systemic con-
centration achieved with 5mg/kg intravenous (IV) bevaci-
zumab. This is a clinically applicable dose that is associated
with hypertension in 42% of patients [34]. Although some
treatment regimens employ up to 15mg/kg of intravenous
bevacizumab [35,36], we were reluctant to administer such
large doses to the forearm arterial circulation with concern
about the potential for systemic spill-over. We did not
assess directly the effect of VEGFi upon the activity of other
endothelial vasomotor pathways, including NO and EDHF.
However, we wished to minimize exposure of healthy
volunteers to bevacizumab and our primary focus was
the assessment of ET-1 signalling in the context of VEGFi.
In conclusion, brief exposure to bevacizumab does not
increase resting vascular tone and has no effect on brady-
kinin-induced vasorelaxation. Moreover, bevacizumab did
not influence endothelial activity as evidenced by no effect
on production of endothelial-derived fibrinolytic factors or
endothelin-1. Future vascular assessment should focus on
effects of longer term exposure to VEGFi in cancer patients.
This will allow the identification of putative vascular mech-
anisms of VEGFi-associated hypertension and thrombosis
in cancer patients treated with VEGFi.
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